Merck & Co.'s New Cholesterol Drug Approval
Merck & Co. has received US regulatory approval for a new pill called Lipfendra, designed to reduce dangerous cholesterol levels and rival existing injectable treatments.
Approval Details
- The US Food and Drug Administration (FDA) approved Lipfendra as a once-daily medication for reducing LDL cholesterol.
- Priced at approximately $3,800 annually, the pill has shown significant reductions in artery-clogging plaques, outperforming traditional statins and other medications.
Market Impact and Projections
- Lipfendra is expected to contribute significantly to Merck’s growth, alongside another drug, Winrevair, for pulmonary arterial hypertension.
- Wall Street analysts predict Lipfendra could generate $4.2 billion in annual peak sales.
- The approval was facilitated through the new Commissioner’s National Priority Voucher program, expediting the process.
Competitive Edge and Clinical Trials
- Clinical trials reported a 56% reduction in artery-clogging plaque, comparable to injectable alternatives.
- Lipfendra targets patients with high cholesterol, including those with heterozygous familial hypercholesterolemia.
- The pill is positioned to replace injectable PCSK9 inhibitors, which initially underperformed despite significant LDL reduction capabilities.
Pricing and Accessibility
- Merck has priced the drug at $10.50 per day, ensuring affordability across various insurance plans, including Medicare.
- The drug aims to ensure wide accessibility regardless of insurance coverage.
Competition
- AstraZeneca Plc is also developing a cholesterol pill, with trials indicating a 50% reduction in LDL cholesterol.
